Freenome Stock
Freenome is a health technology company using accurate, accessible and non-invasive disease screenings to proactively treat cancer and other diseases at their most manageable stages. Freenome does this through a fusion of machine learning, biology and computer science.
Sign up for SecondMarket™ to view the market and buy or sell Freenome Stock
Buy + SellFreenome Funding
Sign up to gain insights into Freenome funding history, including the funding round, time period, and amount raised.
Sign Up to Unlock the Data| Date | Financing Round | Amount | Price per share* | Valuation* |
|---|---|---|---|---|
| Feb 15, 2024 | Series F | 254.00M | ||
| Jan 11, 2022 | Series E | 290.00M | ||
| Nov 22, 2021 | Series D | 243.00M | ||
| Aug 14, 2020 | Series C | 270.00M | ||
| Jun 24, 2019 | Series B | 160.00M | ||
| Aug 14, 2017 | Series A | 8.05M | ||
| Feb 23, 2017 | Series A | 63.95M | ||
| May 23, 2016 | Series Seed | 5.55M |
See Freenome Valuations + Financials
*Sample data + company shown for illustrative purposes only
Gain insights Into Freenome Stock Valuation + Share Prices
View real-time Tape D™ data on Freenome stock including most recent valuation and historical share price information.
Are you an institutional investor or employee shareholder? Sign up to the SecondMarket™ trading platform.
Get Started
Freenome Management Team
Co-Founder, Chief Growth Officer
Charles Roberts
Director
Randal Scott
Co-Founder, COO, Director
Riley Ennis
Director
Peter Kolchinsky
Chief Scientific Officer
Jimmy Lin
CEO, Director
Mike Nolan
Co-Founder, Director
Gabriel Otte
Director
Amir Nashat
Director
Ellen Hukkelhoven
Director
Vijay Pande
Freenome Major Investors
Bain Capital Venture Partners LLC
Andreessen Horowitz LLC; AKA: A16Z
Catalio Capital Management, LP
Charles River Ventures (CRV)
Third Kind Venture Capital
Section 32
Google Ventures (GV)
Rock Springs Capital
Novartis, Inc.
Cormorant Asset Management
Artis Ventures
Colorectal Cancer Alliance
DCVC
Ridgeback Capital
T. Rowe Price Associates, Inc.
BrightEdge
Verily Life Sciences LLC
Kaiser Permanente Ventures
Roche Venture Fund
Spectrum 28 Capital
Polaris Partners
Asset Management Ventures
Innovation Endeavors LLC
RA Capital Management LLC
Janus Henderson
The Founders Fund
Soleus Capital Management
Farallon Capital Management LLC
Cormorant Capital
Fidelity Management & Research Company
Data Collective
F. Hoffmann-La Roche AG
Perceptive Advisors, LLC
Sands Capital Management LLC
EcoR1 Capital
Learn More About Freenome Stock
Buy Freenome Stock
01Freenome stock does not trade on public stock exchanges. Freenome stock is considered a private security and you need to be an accredited investor to trade shares. To invest in Freenome stock you can either buy shares directly through the company or work with a secondary trading marketplace like Nasdaq Private Market.
Learn more about the secondary market for private company shares on the investors page.
Sell Freenome Stock
02Freenome Stock does not trade on public stock exchanges. In order to sell Freenome shares you need to work directly with the company or with a secondary trading marketplace like Nasdaq Private Market. NPM has more than a decade of experience helping sell shares on the private market to our network of institutional investors.
Learn more about NPM services for selling privately held stock on the Employee Shareholders page.
Read more about how to sell private company stock on the private secondary market:
Freenome Stock Price
03Freenome does not have a publicly available stock price because it is privately held and not traded on public stock exchanges. Through the Tape D™ database from Nasdaq Private Market, you can view Freenome share price and other valuable private market data.
Read more about secondary market private company stock prices:
Freenome Stock Ticker Symbol
04There is no ticker symbol for Freenome stock because it is a private company. Private companies do not have ticker symbols like public companies, they are identified primarily by using the company ‘street’ name or legal name.
Criteria to Sell Freenome Stock
05Nasdaq Private Market currently works with employees, ex-employees, and other company investors. In order to sell Freenome stock you need to receive the company’s approval, which Nasdaq Private Market manages on your behalf.
Learn more about selling privately held stock on the Employee Shareholders page.
Read more about how to sell shares of a private company and eligibility for selling privately held stock:
Criteria to Buy or Invest in Freenome Stock
06Currently, Nasdaq Private Market only works with accredited entities and institutional investors to purchase private company stock. In order to invest in Freenome stock, you need to be an accredited entity or institutional investor.
Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.
Freenome Stock Settlement
07Once you buy or sell, stock share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patent-pending Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.
To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.
Freenome IPO
08Freenome is a private company and has not had an IPO. There is currently no Freenome IPO price. Get started to begin exploring the Nasdaq Private Market Tape D™ database and gain access to actionable data related to Freenome IPO.
Learn more about Tape D™ private company stock data for institutional investors on the on the Tape D™ Product Page.
Sign up for SecondMarket™ to view the market and buy or sell Freenome Stock
Buy + Sell*All trademarks are the property of their respective owner(s). Unless expressly stated otherwise, companies listed on this site are not sponsoring, endorsing, or otherwise affiliated with, Nasdaq Private Market, LLC, and none of the statements on this website should be attributed to a listed company.
